<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1193">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 01, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01535976</url>
  </required_header>
  <id_info>
    <org_study_id>STU00048723</org_study_id>
    <nct_id>NCT01535976</nct_id>
  </id_info>
  <brief_title>Ketamine Infusion and Hypoventilation</brief_title>
  <official_title>The Effect of Ketamine in The Prevention of Hypoventilation in Patients With and Without a Positive Berlin Questionnaire Undergoing Deep Sedation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Procedures performed under sedation have the same severity in regards to morbidity and
      mortality as procedures performed under general anesthesia1. The demand for anesthesia care
      outside the operating room has increased tremendously and it poses, according to a closed
      claim analysis, major risks to patients . Both closed claim analysis identified respiratory
      depression due to oversedation as the main risk to patients undergoing procedures under
      sedation. The major problem is that hypoventilation is only detected at very late stages in
      patients receiving supplemental oxygen. Besides the respiratory effects of hypoventilation,
      hypercapnia can also lead to hypertension, tachycardia, cardiac arrhythmias and seizures.

      The incidence of anesthetized patients with obstructive sleep apnea has increased
      substantially over the last years along with the current national obesity epidemic. These
      patients are at increased risk of hypoventilation when exposed to anesthetic drugs. The
      context of the massive increase in procedural sedation and the extremely high prevalence of
      obstructive sleep apnea poses major respiratory risks to patients and it may, in a near
      future, increase malpractice claims to anesthesiologists. The development of safer
      anesthesia regimen for sedation are, therefore, needed. The establishment of safer
      anesthetics regimen for sedation is in direct relationship with the anesthesia patient
      safety foundation priorities. It addresses peri-anesthetic safety problems for healthy
      patient's. It can also be broadly applicable and easily implemented into daily clinical
      care.

      Ketamine has an established effect on analgesia but the effects of ketamine on ventilation
      have not been clearly defined. The lack of validated and sensitive instruments to evaluate
      the effects of ketamine on ventilation is an important reason for the conflicting
      results.The investigators have demonstrated that the transcutaneous carbon dioxide monitor
      is accurate in detecting hypoventilation in patients undergoing deep sedation. Animal data
      suggest that when added to propofol in a sedation regimen, ketamine decreased
      hypoventilation when compared to propofol alone. It is unknown if ketamine added to a
      commonly used sedative agent (propofol) can decrease the incidence and severity of
      hypoventilation in patients undergoing deep sedation. It is also unknown if the effect of
      ketamine on ventilation are different in patients with and without obstructive sleep apnea.

      The investigators hypothesized that patients receiving ketamine and propofol will develop
      less intraoperative hypoventilation than patients receiving propofol alone. The
      investigators also hypothesized that this effect will be even greater in patients with
      obstructive sleep apnea than patients without obstructive sleep apnea.

      Significance: Respiratory depression due to oversedation was identified twice as the major
      factor responsible for claims related to anesthesia. The high prevalence of obstructive
      sleep apnea combined with more complex procedures done in outpatient settings can increase
      physical risks to patients and liability cases to anesthesiologists. The main goal of this
      project is to establish the effect of ketamine in preventing respiratory depression to
      patients undergoing procedures under sedation. If the investigators confirm the their
      hypothesis , their findings can be valuable not only to anesthesiologist but also to other
      specialties ( Emergency medicine, gastroenterologists, cardiologists, radiologists) that
      frequently performed procedural sedation. The research questions is;does ketamine prevent
      hypoventilation during deep sedation? The hypotheses is; ketamine will prevent
      hypoventilation during sedation cases.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Intraoperative Hypoventilation</measure>
    <time_frame>8 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Subjects receiving intraoperative ketamine in addition to propofol will demonstrate less hypoventilation during the surgical procedure.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Hypoventilation</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>.9 normal saline infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infusion of ketamine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Comparator: Placebo
.9 normal saline infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Ketamine infusion .5mg/kg bolus followed by 1.5 mcg/kg/minute until end of case</description>
    <arm_group_label>Ketamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA I,II

          -  Age 18-64

          -  Females undergoing surgical procedures requiring sedation

        Exclusion Criteria:

          -  Pregnant subjects

          -  Breastfeeding

          -  Patients or surgeon request

             ---Drop Out:

          -  Patient or surgeon request,

          -  Conversion to general anesthesia

          -  Inability to obtain data from Co2 monitor
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gildasio De Oliveira, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prentice Womens Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 18, 2014</lastchanged_date>
  <firstreceived_date>September 9, 2011</firstreceived_date>
  <firstreceived_results_date>November 11, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Gildasio De Oliveira</investigator_full_name>
    <investigator_title>Gildasio De Oliveira, M.D. Principal Investigator</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypoventilation</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Hospital based recruitment. From August 2011 to June 2012.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Ketamine</title>
          <description>Infusion of ketamine
Ketamine : Ketamine infusion .5mg/kg bolus followed by 1.5 mcg/kg/minute until end of case</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>.9 normal saline infusion
Placebo : Placebo Comparator: Placebo
.9 normal saline infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ketamine</title>
          <description>Infusion of ketamine
Ketamine : Ketamine infusion .5mg/kg bolus followed by 1.5 mcg/kg/minute until end of case along with propofol 100 mcg/kg/min</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>normal saline infusion
Placebo : Placebo Comparator: Placebo
normal saline infusion along with propofol 100 mcg/kg/min</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="27"/>
                <measurement group_id="B2" value="27"/>
                <measurement group_id="B3" value="54"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="27"/>
                <measurement group_id="B2" value="27"/>
                <measurement group_id="B3" value="54"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="48.4" spread="7.67"/>
                <measurement group_id="B2" value="46.89" spread="7.35"/>
                <measurement group_id="B3" value="47.65" spread="7.55"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="27"/>
                <measurement group_id="B2" value="27"/>
                <measurement group_id="B3" value="54"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="27"/>
                <measurement group_id="B2" value="27"/>
                <measurement group_id="B3" value="54"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Intraoperative Hypoventilation</title>
        <description>Subjects receiving intraoperative ketamine in addition to propofol will demonstrate less hypoventilation during the surgical procedure.</description>
        <time_frame>8 hours</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>The median percentage of the sedation time with TCO2 &gt; 50 mmHg</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Infusion of ketamine
Ketamine : Ketamine infusion .5mg/kg bolus followed by 1.5 mcg/kg/minute until end of case along with propofol 100 mcg/kg/min.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>normal saline infusion
Placebo : Placebo Comparator: Placebo
normal saline infusion along with propofol 100 mcg/kg/min</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                  <measurement group_id="O2" value="26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Intraoperative Hypoventilation</title>
            <description>Subjects receiving intraoperative ketamine in addition to propofol will demonstrate less hypoventilation during the surgical procedure.</description>
            <units>% time</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.2" spread="95" lower_limit="0" upper_limit="83"/>
                  <measurement group_id="O2" value="65" lower_limit="0" upper_limit="88"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>We did not use depth of anesthesia monitor guided protocol due to controversial effects of ketamine of the correlation of processed EEG monitor and clinical levels of sedation. We did not use opioids as part of the protocol.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Gildasio De Oliveira MD</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312-472-3573</phone>
      <email>g-jr@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
